Teva outlicenses Japanese development and commercialization rights to migraine drug fremanezumab to Otsuka
Executive Summary
Otsuka Pharmaceutical Co. Ltd. licensed exclusive Japanese development and commercialization rights to investigational candidate fremanezumab (TEV48125) from Teva Pharmaceutical Industries Ltd.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice